<DOC>
	<DOCNO>NCT00108004</DOCNO>
	<brief_summary>This open-label , multicenter study design investigate clinical utility safety pramlintide treatment subject type 1 type 2 diabetes fail achieve desire level glycemic control use insulin therapy .</brief_summary>
	<brief_title>Clinical Utility Safety Pramlintide Subjects With Type 1 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>The subject clinical diagnosis type 1 diabetes mellitus require treatment insulin minimum 6 month Screening ; OR The subject clinical diagnosis type 2 diabetes require treatment insulin without oral antidiabetic agent minimum 6 month Screening . The subject HbA1c 7.0 % 11.0 % Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Symlin</keyword>
	<keyword>pramlintide acetate</keyword>
</DOC>